ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1755

Dendritic Cell-Specific Loss of Caspase 8 Incites Symptoms of Neuropsychiatric Systemic Lupus Erythematosus

Hadijat Makinde1, Harris R. Perlman2 and Carla Cuda1, 1Northwestern University, Chicago, IL, 2Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Northwestern University, Chicago, IL

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: dendritic cells and neuropsychiatric disorders, SLE

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Systemic Lupus Erythematosus – Animal Models - Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Previous studies implicate dendritic cells (DCs) in the initiation and persistence of systemic lupus erythematosus (SLE), and although DCs from SLE patients exhibit elevated activation, the factors responsible remain largely unknown. Neuropsychiatric symptoms of SLE (NP-SLE), which affect roughly 40-70% of SLE patients, include headaches, cognitive dysfunction and psychiatric disorders, and may be among the earliest symptoms of SLE. Mice with an underlying defect in Fas (MRL/lpr) display cognitive and affective dysfunction characteristic of NP-SLE. We have shown that DC-specific loss of caspase 8, an enzyme in the Fas pathway classically linked to apoptosis initiation and necroptosis suppression, induces a SLE-like disease that originates from heightened DC activation. However, whether there exists a link between caspase 8 signaling, heightened DC activation and NP-SLE is a mystery. To this end, we examined the neurological consequences of DC-specific caspase 8 deletion.

Methods: Mice with caspase 8 flanked by loxP sites (Casp8fl/fl, WT) were bred to mice expressing Cre under control of the CD11c gene promoter (CreCD11c) to generate CreCD11cCasp8flox/floxmice. Neurological deficiency was assessed via 8 tests (exit circle, startle reflex, seeking behavior, beam balancing, round stick balancing, beam walk: 3 cm, beam walk: 2 cm, beam walk:1 cm) with each test providing 0, 0.5 or 1 points depending on the severity of the behavioral deficit and, when combined, provide a neurological severity score (NSS). Cellular infiltration into the brain was assessed using 10-color flow cytometric analysis.

Results: With age, CreCD11cCasp8flox/flox mice develop an inflammatory disease reminiscent of both classic murine models of SLE and human SLE that is characterized by splenomegaly, lymphadenopathy, autoantibodies, elevated serum cytokines, glomerulonephritis, immune complex deposition in the kidney and proteinuria. Strikingly, CreCD11cCasp8flox/floxmice develop neurological deficiencies, with a 4-fold higher NSS than WT mice. These observed behavioral consequences correlate with increased numbers of microglia, as well as cellular infiltration of not only DCs, but also macrophages, lymphocytes and neutrophils. The cellular infiltration is reminiscent of an acute model of traumatic brain injury, wherein physical damage to the brain promotes leakage of the blood-brain barrier. However, in our case, this breach of the blood-brain barrier is the direct result of DC-specific caspase 8 deletion and chronic systemic inflammation.

Conclusion: Our previous studies showed that DC-specific loss of caspase 8 induced a SLE-like disease that originated from heightened DC activation. We now reveal that deletion of caspase 8 in DCs is sufficient to incite symptoms of NP-SLE that correspond with a breach in the blood-brain barrier and leukocyte infiltration. These data substantiate a novel DC-specific mechanism whereby caspase 8 controls DC activation to prevent not only end-organ failure and peripheral pathology associated with SLE-like disease, but also NP-SLE manifestations, thereby highlighting a potentially useful target for therapy.


Disclosure: H. Makinde, None; H. R. Perlman, None; C. Cuda, None.

To cite this abstract in AMA style:

Makinde H, Perlman HR, Cuda C. Dendritic Cell-Specific Loss of Caspase 8 Incites Symptoms of Neuropsychiatric Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/dendritic-cell-specific-loss-of-caspase-8-incites-symptoms-of-neuropsychiatric-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dendritic-cell-specific-loss-of-caspase-8-incites-symptoms-of-neuropsychiatric-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology